AgeX Therapeutics to Participate at Four Conferences in January 2020
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan 14, 2020--
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at the following four conferences this month: Biotech Showcase, January 13-15; Precision Medicine World Conference ( PMWC 2020 ), January 21-24; World Stem Cell Summit, January 21-24; and Longevity Therapeutics, January 28-30.
Details of the company’s presentations follow:
AgeX’s founder and CEO Michael D. West, PhD will deliver a presentation on AgeX and its programs at this investor conference held concurrently with the J.P. Morgan Healthcare Conference.
AgeX will participate in a 90-minute session that will include two talks as well as a panel discussion, on Thursday, January 23, 1:45-3:15pm EST. Dr. West will deliver a 25-minute presentation, “Towards safe in vivo partial reprogramming with induced tissue regeneration” while AgeX’s VP, Discovery Research, Dana Larocca, PhD, will deliver a presentation, “Derivation and uses of highly pure, non-immunogenic lineage-specific stem cell lines.”
Additionally, three AgeX team members will participate on a panel discussion, “The next stem cell revolution: transcending limits on purity, immunogenicity and oncogenicity.” Panel participants include Drs. West and Larocca, in a session moderated by Dr. Aubrey de Grey, AgeX’s VP, New Technology Discovery.
AgeX’s CFO Russell Skibsted will deliver a corporate presentation as part of the Emerging Therapeutics Track.
Dr. Larocca will deliver a presentation on AgeX’s induced tissue regeneration ( iTR ) program.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem ® and UniverCyte ™ manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem ® is AgeX’s delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of AgeX’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov ). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200114005342/en/
CONTACT: Media Contact for AgeX:Bill Douglass
Gotham Communications, LLC
KEYWORD: CALIFORNIA FLORIDA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: RESEARCH MEDICAL DEVICES DIABETES CLINICAL TRIALS CARDIOLOGY STEM CELLS BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE
SOURCE: AgeX Therapeutics, Inc.
Copyright Business Wire 2020.
PUB: 01/14/2020 08:00 AM/DISC: 01/14/2020 08:01 AM